📊 CGON Key Takeaways
Is CG Oncology, Inc. (CGON) a Good Investment?
CG Oncology is a pre-revenue biotech company with severe cash burn (-$132.3M operating cash flow) against minimal revenue ($4.0M), indicating extended path to profitability. Critically low liquidity relative to burn rate (32.5M cash against -$132.5M free cash flow) suggests potential funding challenges within 3-4 quarters without capital raises.
CG Oncology shows very strong liquidity and a clean balance sheet, with $752.60M of equity, minimal long-term debt, and current/quick ratios above 24x, which gives it substantial financial flexibility. However, the business remains deeply unprofitable, with operating margin of -4722.1%, net margin of -3985.0%, and free cash flow of -$132.48M, so the core fundamental story still depends on converting early revenue growth into a scalable commercial base. The sharp revenue increase is encouraging, but growth quality remains unproven given the tiny revenue base relative to ongoing losses and cash burn.
Why Buy CG Oncology, Inc. Stock? CGON Key Strengths
- Strong balance sheet with $752.6M stockholders' equity and zero net debt
- Exceptional liquidity ratios (24.63x current ratio) providing short-term solvency
- Rapid revenue growth (+254.7% YoY) indicating commercial traction in early stage
- Substantial asset base ($791.6M) providing resources for development
- Exceptional balance sheet strength with very low leverage and large equity cushion
- Strong near-term liquidity, reducing immediate financing pressure
- Rapid year-over-year revenue growth suggests improving commercial traction
CGON Stock Risks: CG Oncology, Inc. Investment Risks
- Unsustainable cash burn rate of -$132.3M annually against only $32.5M cash on hand
- Extreme negative profitability metrics (-4722% operating margin, -3985% net margin) with no path to breakeven visible
- Net income loss of -$161.0M in latest period indicates massive R&D and operational expenses
- Minimal revenue base ($4.0M) insufficient to offset operating expenses, requiring continued dilutive financing
- Extreme operating and net losses indicate the business model is not yet self-sustaining
- Heavy negative operating cash flow and free cash flow could erode liquidity over time
- Revenue remains too small relative to expense base, so current growth quality is still uncertain
Key Metrics to Watch
- Quarterly cash burn rate and runway to profitability
- Revenue growth trajectory and pipeline advancement milestones
- Capital raised and dilution impact on shareholder equity
- Operating expense reduction and path toward operating cash flow breakeven
- Quarterly revenue growth relative to operating expense growth
- Cash burn trajectory and ending cash balance
CG Oncology, Inc. (CGON) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 24.63x current ratio provides a solid financial cushion.
CGON Profit Margin, ROE & Profitability Analysis
CGON vs Healthcare Sector: How CG Oncology, Inc. Compares
How CG Oncology, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is CG Oncology, Inc. Stock Overvalued? CGON Valuation Analysis 2026
Based on fundamental analysis, CG Oncology, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
CG Oncology, Inc. Balance Sheet: CGON Debt, Cash & Liquidity
CGON Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: CG Oncology, Inc.'s revenue has grown significantly by 255% over the 5-year period, indicating strong business expansion. The most recent EPS of $-15.65 indicates the company is currently unprofitable.
CGON Revenue Growth, EPS Growth & YoY Performance
CGON Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $43.0K | -$16.9M | $-0.30 |
| Q2 2025 | N/A | -$16.9M | $-0.28 |
| Q1 2025 | $52.0K | -$16.9M | $-0.36 |
| Q3 2024 | $9.0K | -$8.7M | $-0.30 |
| Q2 2024 | N/A | -$8.7M | $-0.28 |
| Q1 2024 | $194.0K | -$8.7M | $-0.36 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CG Oncology, Inc. Dividends, Buybacks & Capital Allocation
CGON SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for CG Oncology, Inc. (CIK: 0001991792)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CGON
What is the AI rating for CGON?
CG Oncology, Inc. (CGON) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 83% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CGON's key strengths?
Claude: Strong balance sheet with $752.6M stockholders' equity and zero net debt. Exceptional liquidity ratios (24.63x current ratio) providing short-term solvency. ChatGPT: Exceptional balance sheet strength with very low leverage and large equity cushion. Strong near-term liquidity, reducing immediate financing pressure.
What are the risks of investing in CGON?
Claude: Unsustainable cash burn rate of -$132.3M annually against only $32.5M cash on hand. Extreme negative profitability metrics (-4722% operating margin, -3985% net margin) with no path to breakeven visible. ChatGPT: Extreme operating and net losses indicate the business model is not yet self-sustaining. Heavy negative operating cash flow and free cash flow could erode liquidity over time.
What is CGON's revenue and growth?
CG Oncology, Inc. reported revenue of $4.0M.
Does CGON pay dividends?
CG Oncology, Inc. does not currently pay dividends.
Where can I find CGON SEC filings?
Official SEC filings for CG Oncology, Inc. (CIK: 0001991792) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CGON's EPS?
CG Oncology, Inc. has a diluted EPS of $-2.08.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CGON a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, CG Oncology, Inc. has a SELL rating with 83% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CGON stock overvalued or undervalued?
Valuation metrics for CGON: ROE of -21.4% (sector avg: 15%), net margin of -3,985.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CGON stock in 2026?
Our dual AI analysis gives CG Oncology, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CGON's free cash flow?
CG Oncology, Inc.'s operating cash flow is $-132.3M, with capital expenditures of $134.0K. FCF margin is -3,279.2%.
How does CGON compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -3,985.0% (avg: 12%), ROE -21.4% (avg: 15%), current ratio 24.63 (avg: 2).